US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Entrada Therapeutics, Inc.

9.04

+0.09501.06%

Volume:52.46K

Turnover:470.44K

Market Cap:339.67M

PE:5.38

High:9.11

Open:8.78

Low:8.69

Close:8.94

Loading ...

Overview Company News Filings

BRIEF-Entrada Therapeutics Inc - Approves Strategic Plan Focusing On DMD Programs - SEC Filing

Entrada Therapeutics Inc - Expects Cash Runway to Extend Into Q2 2027 - SEC Filing

THOMSON REUTERS

Entrada Therapeutics Inc - to Reduce Workforce by Approximately 20% Under New Plan - SEC Filing

THOMSON REUTERS

Ultragenyx (RARE) Soars 9.2%: Is Further Upside Left in the Stock?

Positive Outlook on Entrada Therapeutics Inc Due to Promising Developments in Duchenne Muscular Dystrophy Treatment

BUZZ-Entrada Therapeutics rises on UK approval for muscle-wasting drug study

Entrada Therapeutics Duchenne Muscular Dystrophy Investigational Treatment Study Gets Approval in UK

MT Newswires Live

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Elevate-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of Entr-601-45 in People Living With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

THOMSON REUTERS

Entrada Therapeutics- Expects to Progress Elevate-45 Into Global Clinical Development in 2025

THOMSON REUTERS

Entrada Therapeutics Inc - on Track to Initiate Elevate-45-201 Study in Q3 2025

THOMSON REUTERS

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

Entrada Therapeutics, Inc. Just Beat EPS By 55%: Here's What Analysts Think Will Happen Next

Simply Wall St.

Entrada Therapeutics: Regulatory Progress and Strategic Trials Drive Buy Rating

Entrada Therapeutics, Inc. (TRDA) Surpasses Q4 Earnings and Revenue Estimates

Entrada Therapeutics sees cash runway into 2Q27

Entrada Therapeutics, Inc. Q4 Operating Expenses USD 43.265 Million

THOMSON REUTERS

Entrada Therapeutics, Inc. Q4 Income From Operations USD -5.867 Million

THOMSON REUTERS

Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Biotech Stock Roundup: BLUE Down on Update, News From GILD, TRDA

Entrada Therapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/TRDA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TRDA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TRDA\",,,,,undefined,":{"symbol":"TRDA","market":"US","secType":"STK","nameCN":"Entrada Therapeutics, Inc.","latestPrice":9.035,"timestamp":1746035800407,"preClose":8.94,"halted":0,"volume":52460,"delay":0,"floatShares":20987600,"shares":37594630,"eps":1.68,"marketStatus":"Trading","change":0.095,"latestTime":"04-30 13:57:55 EDT","open":8.78,"high":9.11,"low":8.69,"amount":470442.28948000004,"amplitude":0.04698,"askPrice":9.11,"askSize":17,"bidPrice":9,"bidSize":60,"shortable":3,"etf":0,"ttmEps":1.68,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1746043200000},"marketStatusCode":2,"adr":0,"listingDate":1635480000000,"exchange":"NASDAQ","adjPreClose":8.94,"postHourTrading":{"tag":"盘后","latestPrice":8.94,"preClose":8.94,"latestTime":"18:11 EDT","volume":1122,"amount":10033.44,"timestamp":1745964679882},"volumeRatio":0.646319,"impliedVol":1.142,"impliedVolPercentile":0.5522},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TRDA\",,,,,undefined,":{"symbol":"TRDA","floatShares":20987600,"roa":"5.90%","roe":"19.56%","lyrEps":1.75911,"volumeRatio":0.646319,"shares":37594630,"dividePrice":0,"high":9.11,"amplitude":0.04698,"preClose":8.94,"low":8.69,"week52Low":7.1,"pbRate":"0.79","psRate":"1.61","week52High":21.79,"institutionHeld":0,"latestPrice":9.035,"committee":0.558442,"eps":1.68,"divideRate":0,"volume":52460,"delay":0,"ttmEps":1.68,"open":8.78,"prevYearClose":17.29,"prevWeekClose":8.84,"prevMonthClose":9.04,"prevQuarterClose":9.04,"fiveDayClose":8.71,"twentyDayClose":8.76,"sixtyDayClose":13.33},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TRDA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531713030","title":"BRIEF-Entrada Therapeutics Inc - Approves Strategic Plan Focusing On DMD Programs - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2531713030","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531713030?lang=en_us&edition=fundamental","pubTime":"2025-04-30 05:44","pubTimestamp":1745963097,"startTime":"0","endTime":"0","summary":"BRIEF-Entrada Therapeutics Inc - Approves Strategic Plan Focusing On DMD Programs - SEC FilingApril 29  - Entrada Therapeutics Inc TRDA.O:ENTRADA THERAPEUTICS INC - APPROVES STRATEGIC PLAN FOCUSING ON DMD PROGRAMS - SEC FILINGENTRADA THERAPEUTICS INC - TO REDUCE WORKFORCE BY APPROXIMATELY 20% UNDER NEW PLAN - SEC FILINGENTRADA THERAPEUTICS INC - EXPECTS CASH RUNWAY TO EXTEND INTO Q2 2027 - SEC FILINGSource text: [ID:n0001104659-25-041204]Further company coverage: TRDA.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R7226:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TRDA"],"gpt_icon":0},{"id":"2531379158","title":"Entrada Therapeutics Inc - Expects Cash Runway to Extend Into Q2 2027 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2531379158","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531379158?lang=en_us&edition=fundamental","pubTime":"2025-04-30 04:09","pubTimestamp":1745957343,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R7226:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TRDA"],"gpt_icon":0},{"id":"2531309791","title":"Entrada Therapeutics Inc - to Reduce Workforce by Approximately 20% Under New Plan - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2531309791","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531309791?lang=en_us&edition=fundamental","pubTime":"2025-04-30 04:09","pubTimestamp":1745957343,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R7226:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TRDA"],"gpt_icon":0},{"id":"2526949435","title":"Ultragenyx (RARE) Soars 9.2%: Is Further Upside Left in the Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2526949435","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526949435?lang=en_us&edition=fundamental","pubTime":"2025-04-10 21:30","pubTimestamp":1744291800,"startTime":"0","endTime":"0","summary":"Ultragenyx  shares ended the last trading session 9.2% higher at $33.91. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 19% loss over the past four weeks.The rise in share price came after President Trump announced a 90-day pause on his sweeping tariffs against non-retaliating countries.This biotechnology company is expected to post quarterly loss of $1.58 per share in its upcoming report, which represents a year-over-year change of +22.2%. Revenues are expected to be $142.49 million, up 30.9% from the year-ago quarter.Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.Ultragenyx is part of the Zacks Medical - Biomedical and Genetics industry. Entrada Therapeutics, Inc. , another stock in the same industry,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ultragenyx-rare-soars-9-2-133000725.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","TRDA","RARE"],"gpt_icon":0},{"id":"2522709798","title":"Positive Outlook on Entrada Therapeutics Inc Due to Promising Developments in Duchenne Muscular Dystrophy Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2522709798","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522709798?lang=en_us&edition=fundamental","pubTime":"2025-03-25 02:55","pubTimestamp":1742842516,"startTime":"0","endTime":"0","summary":"William Blair analyst Myles Minter has reiterated their bullish stance on TRDA stock, giving a Buy rating today. Myles Minter has given his Buy rat...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/positive-outlook-on-entrada-therapeutics-inc-due-to-promising-developments-in-duchenne-muscular-dystrophy-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/positive-outlook-on-entrada-therapeutics-inc-due-to-promising-developments-in-duchenne-muscular-dystrophy-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","TRDA"],"gpt_icon":0},{"id":"2521773805","title":"BUZZ-Entrada Therapeutics rises on UK approval for muscle-wasting drug study","url":"https://stock-news.laohu8.com/highlight/detail?id=2521773805","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521773805?lang=en_us&edition=fundamental","pubTime":"2025-03-24 22:39","pubTimestamp":1742827145,"startTime":"0","endTime":"0","summary":"BUZZ-Entrada Therapeutics rises on UK approval for muscle-wasting drug study** Drug developer Entrada Therapeutics' TRDA.O shares rise 2.5% to $10.75** Company says it has received authorization from UK's regulatory agency to begin an early-stage study for an experimental drug, ENTR-601-45, for potential treatment of Duchenne muscular dystrophy, a type of muscle-wasting disorder** Entrada says it is on track to start study in Q3 2025** Company's shares have fallen 22.5% in past 12 months  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nL3N3Q7150:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TRDA"],"gpt_icon":0},{"id":"2521744366","title":"Entrada Therapeutics Duchenne Muscular Dystrophy Investigational Treatment Study Gets Approval in UK","url":"https://stock-news.laohu8.com/highlight/detail?id=2521744366","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521744366?lang=en_us&edition=fundamental","pubTime":"2025-03-24 19:33","pubTimestamp":1742815991,"startTime":"0","endTime":"0","summary":"Entrada Therapeutics  said Monday it has received approval from the UK's Medicines and Healthcare Products Regulatory Agency and Research Ethics Committee to launch a phase 1/2 multiple ascending dose trial of its experimental ENTR-601-45 treatment of Duchenne muscular dystrophy.The clinical study covers patients with a confirmed mutation in the Duchenne muscular dystrophy gene amenable to exon 45 skipping.Entrada said it is on course to begin the trial in Q3.Duchenne muscular dystrophy causes skeletal and heart muscle weakness that quickly gets worse with time.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","TRDA","LENZ"],"gpt_icon":0},{"id":"2521822746","title":"Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Elevate-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of Entr-601-45 in People Living With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping","url":"https://stock-news.laohu8.com/highlight/detail?id=2521822746","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521822746?lang=en_us&edition=fundamental","pubTime":"2025-03-24 19:03","pubTimestamp":1742814189,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nFWN3Q5088:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TRDA"],"gpt_icon":0},{"id":"2521746507","title":"Entrada Therapeutics- Expects to Progress Elevate-45 Into Global Clinical Development in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2521746507","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521746507?lang=en_us&edition=fundamental","pubTime":"2025-03-24 19:03","pubTimestamp":1742814189,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nFWN3Q5088:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TRDA","BK4139"],"gpt_icon":0},{"id":"2521468217","title":"Entrada Therapeutics Inc - on Track to Initiate Elevate-45-201 Study in Q3 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2521468217","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521468217?lang=en_us&edition=fundamental","pubTime":"2025-03-24 19:03","pubTimestamp":1742814189,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nFWN3Q5088:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TRDA"],"gpt_icon":0},{"id":"2521759746","title":"Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping","url":"https://stock-news.laohu8.com/highlight/detail?id=2521759746","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521759746?lang=en_us&edition=fundamental","pubTime":"2025-03-24 19:00","pubTimestamp":1742814000,"startTime":"0","endTime":"0","summary":"– Company on track to initiate ELEVATE-45-201 study in Q3 2025 – – ELEVATE-45 regulatory filings submitted in the EU, with regulatory review ongoing – – ELEVATE-45 is the second of three novel exon sk","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/24/3047704/0/en/Entrada-Therapeutics-Receives-Authorization-in-the-United-Kingdom-to-Initiate-ELEVATE-45-201-a-Phase-1-2-Multiple-Ascending-Dose-Clinical-Study-of-ENTR-601-45-in-People-Living-with.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","PMO","ENTR","UBCP","LENZ","BK4139","TRDA"],"gpt_icon":0},{"id":"2516351256","title":"Entrada Therapeutics, Inc. Just Beat EPS By 55%: Here's What Analysts Think Will Happen Next","url":"https://stock-news.laohu8.com/highlight/detail?id=2516351256","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516351256?lang=en_us&edition=fundamental","pubTime":"2025-03-02 20:46","pubTimestamp":1740919601,"startTime":"0","endTime":"0","summary":"Entrada Therapeutics, Inc.  just released its latest annual results and things are looking bullish. Entrada Therapeutics delivered a significant beat to revenue and earnings per share  expectations, hitting US$211m-13% above indicated-andUS$1.68-55% above forecasts- respectively Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. We thought readers would find it interesting to see the analysts latest  post-earnings forecasts for next year.The most important thing to take away is that the analysts increased their loss per share esti","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/entrada-therapeutics-inc-just-beat-124641450.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TRDA"],"gpt_icon":0},{"id":"2514354491","title":"Entrada Therapeutics: Regulatory Progress and Strategic Trials Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2514354491","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514354491?lang=en_us&edition=fundamental","pubTime":"2025-02-28 07:15","pubTimestamp":1740698114,"startTime":"0","endTime":"0","summary":"William Blair analyst Myles Minter has maintained their bullish stance on TRDA stock, giving a Buy rating today. Myles Minter has given his Buy rat...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/entrada-therapeutics-regulatory-progress-and-strategic-trials-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/entrada-therapeutics-regulatory-progress-and-strategic-trials-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRGS","LENZ","TRDA"],"gpt_icon":0},{"id":"2514389834","title":"Entrada Therapeutics, Inc. (TRDA) Surpasses Q4 Earnings and Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2514389834","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514389834?lang=en_us&edition=fundamental","pubTime":"2025-02-27 21:25","pubTimestamp":1740662706,"startTime":"0","endTime":"0","summary":"Entrada Therapeutics, Inc.  came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.66 per share. This compares to loss of $0.29 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 104.55%. A quarter ago, it was expected that this company would post a loss of $0.67 per share when it actually produced a loss of $0.35, delivering a surprise of 47.76%.Entrada Therapeutics , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $37.4 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 173.66%. This compares to year-ago revenues of $41.85 million. The company has topped consensus revenue estimates four times over the last four quarters.Entrada Therapeutics shares have lost about 30.5% since the beginning of the year versus the S&P 500's gain of 1.3%.While Entrada Therapeutics has underperformed","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/entrada-therapeutics-inc-trda-surpasses-132506141.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TRDA"],"gpt_icon":0},{"id":"2514806778","title":"Entrada Therapeutics sees cash runway into 2Q27","url":"https://stock-news.laohu8.com/highlight/detail?id=2514806778","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514806778?lang=en_us&edition=fundamental","pubTime":"2025-02-27 20:20","pubTimestamp":1740658859,"startTime":"0","endTime":"0","summary":"Cash, cash equivalents and marketable securities were $420.0 million as of December 31, 2024, compared to $352.0 million as of December 31, 2023. T...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/entrada-therapeutics-sees-cash-runway-into-2q27?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/entrada-therapeutics-sees-cash-runway-into-2q27?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","TRDA","BK4139"],"gpt_icon":0},{"id":"2514803067","title":"Entrada Therapeutics, Inc. Q4 Operating Expenses USD 43.265 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514803067","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514803067?lang=en_us&edition=fundamental","pubTime":"2025-02-27 20:00","pubTimestamp":1740657601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nPLX2888B8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TRDA"],"gpt_icon":0},{"id":"2514380340","title":"Entrada Therapeutics, Inc. Q4 Income From Operations USD -5.867 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514380340","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514380340?lang=en_us&edition=fundamental","pubTime":"2025-02-27 20:00","pubTimestamp":1740657601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nPLX2888B8:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TRDA"],"gpt_icon":0},{"id":"2514054488","title":"Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2514054488","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514054488?lang=en_us&edition=fundamental","pubTime":"2025-02-27 20:00","pubTimestamp":1740657600,"startTime":"0","endTime":"0","summary":"– Received FDA authorization to initiate ELEVATE-44-102 in the U.S. –。– Received MHRA authorization to initiate ELEVATE-44-201 in the U.K. –。– Submitted regulatory filings to support global clinical studies for ENTR-601-44 in the EU, and ENTR-601-45 in the U.K. and EU –。BOSTON, Feb. 27, 2025  -- Entrada Therapeutics, Inc.  today reported financial results for the fourth quarter and full year ended December 31, 2024 and highlighted recent business updates.“We are thrilled to begin 2025 with significant momentum. The entire Entrada team has been laser focused on advancing our Duchenne muscular dystrophy franchise, driven by our commitment to bringing a potential best-in-class therapy to patients and their families,” said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics. “The positive data we have presented to date has supported regulatory clearance in multiple geographies for our ELEVATE-44 program and has accelerated the pace at which we are advancing our exon 45, 50 and 51 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/entrada-therapeutics-reports-fourth-quarter-120000132.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","TRDA","BK4139"],"gpt_icon":0},{"id":"2514852178","title":"Biotech Stock Roundup: BLUE Down on Update, News From GILD, TRDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2514852178","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514852178?lang=en_us&edition=fundamental","pubTime":"2025-02-26 22:19","pubTimestamp":1740579540,"startTime":"0","endTime":"0","summary":"It was a busy week for the biotech sector. While the fourth-quarter earnings season is nearing the end, other pipeline and regulatory updates were in focus.bluebird bio’s BLUE shares plunged after the company announced that it has entered into a definitive agreement to be acquired by funds managed by global investment firms Carlyle and SK Capital Partners, LP.Gilead Sciences, Inc. GILD announced that the European Medicines Agency  has validated the company’s marketing authorization application and EU-Medicines for all applications for its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir. Gilead is seeking approval for lenacapavir for the prevention of HIV as pre-exposure prophylaxis .Both these applications are being assessed under an accelerated assessment review timeline as the EMA’s Committee for Medicinal Products for Human Use  determined that twice-yearly lenacapavir for HIV prevention is a product of major interest for public health and therapeutic innovation.BioMarin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biotech-stock-roundup-blue-down-141900146.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0058720904.USD","BK4583","LU2468319806.SGD","IE00BSNM7G36.USD","LU1066053197.SGD","IE00B3T34201.USD","LU0889565916.HKD","IE00BKVL7J92.USD","BLUE","LU1066051498.USD","LU1430594728.SGD","BMRN","BK4532","BK4139","BK4568","BK4087","LU0234570918.USD","LU2089984988.USD","IE0002270589.USD","GILD","BK4585","LU0109394709.USD","IE00B19Z3581.USD","BK4578","LU0289739699.SGD","LU1585245621.USD","BK4588","LU1839511570.USD","IE00B19Z3B42.SGD","BK4566","IE00B7SZLL34.SGD","BK4556","LU1571399168.USD","IE00BZ1G4Q59.USD","LU2087621335.USD","CHMP","BK4550","LU0320765992.SGD","TRDA"],"gpt_icon":0},{"id":"2514095409","title":"Entrada Therapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2514095409","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514095409?lang=en_us&edition=fundamental","pubTime":"2025-02-25 20:39","pubTimestamp":1740487140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TRDA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 25, 2025 07:39 ET (12:39 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","TRDA"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":57,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TRDA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-02-27","symbol":"TRDA","fiscalQuarterEnding":"2024/12","expectedEps":-0.66,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"pre","actualEps":0.03},{"market":"US","date":"2024-11-05","symbol":"TRDA","fiscalQuarterEnding":"2024/09","expectedEps":-0.67,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730782800000,"reportTimeType":"pre","actualEps":-0.35},{"market":"US","date":"2024-08-13","symbol":"TRDA","fiscalQuarterEnding":"2024/06","expectedEps":0.65,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"pre","actualEps":1.55},{"market":"US","date":"2024-05-07","symbol":"TRDA","fiscalQuarterEnding":"2024/03","expectedEps":-0.38,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715054400000,"reportTimeType":"pre","actualEps":0.68},{"market":"US","date":"2024-03-13","symbol":"TRDA","fiscalQuarterEnding":"2023/12","expectedEps":-0.07,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1710302400000,"reportTimeType":"pre","actualEps":-0.29}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TRDA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TRDA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":5,"updateTime":1733457600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TRDA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TRDA","date":"2025-04-29","current":4.815239,"percent":0.757042,"low":-69.405148,"twenty":-10.961909,"median":-5.502472,"eighty":5.557476,"high":25.975557,"avg":-6.372253,"sd":16.456836,"marketCap":316004890},"quantilePoints":[{"date":"2021-10-29","current":-7.394936,"twenty":-17.597525,"median":-17.597525,"eighty":-11.475972,"marketCap":251013723},{"date":"2021-11-05","current":-21.790051,"twenty":-21.952046,"median":-20.803996,"eighty":-17.597525,"marketCap":739641498},{"date":"2021-11-12","current":-28.525158,"twenty":-25.58108,"median":-21.983741,"eighty":-18.485692,"marketCap":968257962},{"date":"2021-11-19","current":-28.868516,"twenty":-29.41789,"median":-24.54132,"eighty":-20.606786,"marketCap":979912918},{"date":"2021-11-26","current":-25.452541,"twenty":-28.824496,"median":-24.607351,"eighty":-21.353369,"marketCap":863961039},{"date":"2021-12-03","current":-23.533255,"twenty":-28.623764,"median":-25.505365,"eighty":-21.812942,"marketCap":798812818},{"date":"2021-12-10","current":-15.265518,"twenty":-28.187082,"median":-23.647708,"eighty":-19.069596,"marketCap":631748205},{"date":"2021-12-17","current":-11.577357,"twenty":-26.820692,"median":-22.432748,"eighty":-16.202556,"marketCap":479117339},{"date":"2021-12-23","current":-12.836913,"twenty":-26.764346,"median":-21.904504,"eighty":-14.360448,"marketCap":531242809},{"date":"2021-12-31","current":-12.912336,"twenty":-26.676305,"median":-20.53107,"eighty":-13.447835,"marketCap":534364094},{"date":"2022-01-07","current":-8.930026,"twenty":-26.218494,"median":-18.937535,"eighty":-12.769033,"marketCap":369560215},{"date":"2022-01-14","current":-6.516506,"twenty":-25.584602,"median":-17.597525,"eighty":-11.577357,"marketCap":269679075},{"date":"2022-01-21","current":-6.101682,"twenty":-25.577558,"median":-15.559666,"eighty":-10.093042,"marketCap":252512005},{"date":"2022-01-28","current":-7.021837,"twenty":-25.519451,"median":-14.360448,"eighty":-7.766209,"marketCap":290591689},{"date":"2022-02-04","current":-7.715724,"twenty":-25.463106,"median":-13.5308,"eighty":-7.379146,"marketCap":319307516},{"date":"2022-02-11","current":-8.537829,"twenty":-24.100237,"median":-13.16123,"eighty":-7.512789,"marketCap":353329529},{"date":"2022-02-18","current":-11.275667,"twenty":-23.579036,"median":-12.802973,"eighty":-7.548286,"marketCap":466632197},{"date":"2022-02-25","current":-9.126125,"twenty":-23.517408,"median":-12.086459,"eighty":-7.649352,"marketCap":377675557},{"date":"2022-03-04","current":-7.813773,"twenty":-22.862386,"median":-11.577357,"eighty":-7.720249,"marketCap":323365188},{"date":"2022-03-11","current":-6.388288,"twenty":-22.163344,"median":-11.204016,"eighty":-7.720249,"marketCap":264372890},{"date":"2022-03-18","current":-6.017184,"twenty":-21.936199,"median":-10.78542,"eighty":-7.363356,"marketCap":307827117},{"date":"2022-03-25","current":-6.255428,"twenty":-21.835832,"median":-10.117931,"eighty":-6.952448,"marketCap":320015196},{"date":"2022-04-01","current":-5.638438,"twenty":-21.46254,"median":-9.64654,"eighty":-6.638691,"marketCap":288451197},{"date":"2022-04-08","current":-4.502198,"twenty":-20.388445,"median":-9.144981,"eighty":-6.309439,"marketCap":230323437},{"date":"2022-04-14","current":-4.948141,"twenty":-19.729901,"median":-9.028075,"eighty":-6.17703,"marketCap":253137020},{"date":"2022-04-22","current":-4.107655,"twenty":-19.333718,"median":-8.726386,"eighty":-6.029276,"marketCap":210139396},{"date":"2022-04-29","current":-3.666235,"twenty":-18.754411,"median":-8.454865,"eighty":-5.912113,"marketCap":187557252},{"date":"2022-05-06","current":-3.457787,"twenty":-18.126844,"median":-8.349273,"eighty":-5.760614,"marketCap":176893461},{"date":"2022-05-13","current":-2.854496,"twenty":-17.597525,"median":-7.941992,"eighty":-5.364762,"marketCap":183969409},{"date":"2022-05-20","current":-2.883329,"twenty":-16.900041,"median":-7.813773,"eighty":-4.563286,"marketCap":185827686},{"date":"2022-05-27","current":-3.373495,"twenty":-15.618496,"median":-7.753435,"eighty":-4.36536,"marketCap":217418392},{"date":"2022-06-03","current":-3.200495,"twenty":-15.214231,"median":-7.632759,"eighty":-4.157927,"marketCap":206268731},{"date":"2022-06-10","current":-4.55566,"twenty":-14.879355,"median":-7.394936,"eighty":-4.140761,"marketCap":293607743},{"date":"2022-06-17","current":-4.11355,"twenty":-14.259382,"median":-7.131199,"eighty":-4.140761,"marketCap":265114165},{"date":"2022-06-24","current":-4.714243,"twenty":-13.855117,"median":-6.935101,"eighty":-4.15057,"marketCap":303828266},{"date":"2022-07-01","current":-5.766658,"twenty":-13.576054,"median":-6.811331,"eighty":-4.187355,"marketCap":371655372},{"date":"2022-07-08","current":-5.656131,"twenty":-13.503648,"median":-6.516506,"eighty":-4.216733,"marketCap":364531977},{"date":"2022-07-15","current":-5.209215,"twenty":-13.455377,"median":-6.350577,"eighty":-4.227922,"marketCap":335728686},{"date":"2022-07-22","current":-5.233243,"twenty":-13.218551,"median":-6.255428,"eighty":-4.255794,"marketCap":337277250},{"date":"2022-07-29","current":-6.151102,"twenty":-12.962115,"median":-6.178897,"eighty":-4.266149,"marketCap":396432396},{"date":"2022-08-05","current":-5.21402,"twenty":-12.851998,"median":-6.151102,"eighty":-4.298784,"marketCap":336038398},{"date":"2022-08-12","current":-5.083828,"twenty":-12.782609,"median":-6.05057,"eighty":-4.359782,"marketCap":395150717},{"date":"2022-08-19","current":-5.22471,"twenty":-12.238059,"median":-6.026259,"eighty":-4.396116,"marketCap":406101054},{"date":"2022-08-26","current":-5.860692,"twenty":-12.075145,"median":-5.963285,"eighty":-4.405727,"marketCap":455534002},{"date":"2022-09-02","current":-5.309239,"twenty":-11.675406,"median":-5.919443,"eighty":-4.443999,"marketCap":412671256},{"date":"2022-09-09","current":-6.005599,"twenty":-11.577357,"median":-5.919443,"eighty":-4.466633,"marketCap":466797205},{"date":"2022-09-16","current":-5.599054,"twenty":-11.396343,"median":-5.874796,"eighty":-4.487556,"marketCap":435197663},{"date":"2022-09-23","current":-6.074028,"twenty":-11.266616,"median":-5.860692,"eighty":-4.499555,"marketCap":472115940},{"date":"2022-09-30","current":-6.343716,"twenty":-11.192702,"median":-5.898062,"eighty":-4.525626,"marketCap":493078013},{"date":"2022-10-07","current":-5.961322,"twenty":-11.10672,"median":-5.888899,"eighty":-4.547138,"marketCap":463355671},{"date":"2022-10-14","current":-6.243086,"twenty":-10.903079,"median":-5.892909,"eighty":-4.553823,"marketCap":485256344},{"date":"2022-10-21","current":-7.587503,"twenty":-10.513899,"median":-5.919443,"eighty":-4.571231,"marketCap":589753842},{"date":"2022-10-28","current":-9.117079,"twenty":-10.255954,"median":-5.957297,"eighty":-4.615058,"marketCap":708643211},{"date":"2022-11-04","current":-8.909464,"twenty":-10.100584,"median":-5.973297,"eighty":-4.663727,"marketCap":692505938},{"date":"2022-11-11","current":-6.743676,"twenty":-9.96784,"median":-6.011392,"eighty":-4.695302,"marketCap":596370284},{"date":"2022-11-18","current":-6.332606,"twenty":-9.758166,"median":-6.033802,"eighty":-4.710399,"marketCap":560017708},{"date":"2022-11-25","current":-5.226969,"twenty":-9.516814,"median":-6.017184,"eighty":-4.72039,"marketCap":462241813},{"date":"2022-12-02","current":-6.488529,"twenty":-9.262707,"median":-6.011392,"eighty":-4.755372,"marketCap":573806616},{"date":"2022-12-09","current":-6.757851,"twenty":-9.16356,"median":-6.033802,"eighty":-4.809238,"marketCap":597623821},{"date":"2022-12-16","current":-7.505574,"twenty":-9.145735,"median":-6.049635,"eighty":-4.867597,"marketCap":663747905},{"date":"2022-12-23","current":-5.304931,"twenty":-9.135788,"median":-6.033802,"eighty":-4.931786,"marketCap":469136267},{"date":"2022-12-30","current":-4.791093,"twenty":-9.127349,"median":-6.017184,"eighty":-4.849836,"marketCap":423695546},{"date":"2023-01-06","current":-5.04624,"twenty":-9.126125,"median":-6.001574,"eighty":-4.798181,"marketCap":446259214},{"date":"2023-01-13","current":-4.858424,"twenty":-9.117079,"median":-5.963335,"eighty":-4.832074,"marketCap":429649847},{"date":"2023-01-20","current":-4.737938,"twenty":-9.004373,"median":-5.936357,"eighty":-4.79343,"marketCap":418994782},{"date":"2023-01-27","current":-4.273712,"twenty":-8.93926,"median":-5.907226,"eighty":-4.785423,"marketCap":377941441},{"date":"2023-02-03","current":-5.10294,"twenty":-8.913576,"median":-5.876808,"eighty":-4.726537,"marketCap":451273363},{"date":"2023-02-10","current":-5.73372,"twenty":-8.859542,"median":-5.853158,"eighty":-4.736273,"marketCap":507055765},{"date":"2023-02-17","current":-3.919341,"twenty":-8.845264,"median":-5.829192,"eighty":-4.699967,"marketCap":346603013},{"date":"2023-02-24","current":-3.926429,"twenty":-8.842391,"median":-5.815955,"eighty":-4.628083,"marketCap":347229782},{"date":"2023-03-03","current":-3.766962,"twenty":-8.772142,"median":-5.776163,"eighty":-4.547138,"marketCap":333127489},{"date":"2023-03-10","current":-4.254453,"twenty":-8.615439,"median":-5.76082,"eighty":-4.499555,"marketCap":402539289},{"date":"2023-03-17","current":-5.429059,"twenty":-8.539287,"median":-5.747436,"eighty":-4.511816,"marketCap":513675855},{"date":"2023-03-24","current":-5.271746,"twenty":-8.488051,"median":-5.734949,"eighty":-4.524607,"marketCap":498791493},{"date":"2023-03-31","current":-5.068986,"twenty":-8.454865,"median":-5.728214,"eighty":-4.53629,"marketCap":479607205},{"date":"2023-04-06","current":-4.883706,"twenty":-8.451848,"median":-5.696978,"eighty":-4.543209,"marketCap":462076735},{"date":"2023-04-14","current":-5.932462,"twenty":-8.421679,"median":-5.680564,"eighty":-4.551986,"marketCap":561305812},{"date":"2023-04-21","current":-5.257762,"twenty":-8.349273,"median":-5.670547,"eighty":-4.55566,"marketCap":497468439},{"date":"2023-04-28","current":-4.805367,"twenty":-8.340215,"median":-5.658534,"eighty":-4.562088,"marketCap":454664626},{"date":"2023-05-05","current":-4.191543,"twenty":-8.062667,"median":-5.64652,"eighty":-4.528859,"marketCap":396587028},{"date":"2023-05-12","current":-5.064425,"twenty":-7.979703,"median":-5.633268,"eighty":-4.502198,"marketCap":403224467},{"date":"2023-05-19","current":-5.277006,"twenty":-7.913544,"median":-5.617686,"eighty":-4.518228,"marketCap":420149939},{"date":"2023-05-26","current":-4.970025,"twenty":-7.90428,"median":-5.592298,"eighty":-4.528859,"marketCap":395708454},{"date":"2023-06-02","current":-4.76989,"twenty":-7.868078,"median":-5.581432,"eighty":-4.538767,"marketCap":379773885},{"date":"2023-06-09","current":-6.116634,"twenty":-7.822824,"median":-5.586978,"eighty":-4.549103,"marketCap":487000254},{"date":"2023-06-16","current":-6.016566,"twenty":-7.801706,"median":-5.597041,"eighty":-4.554742,"marketCap":479032969},{"date":"2023-06-23","current":-6.667006,"twenty":-7.789638,"median":-5.618244,"eighty":-4.559517,"marketCap":530820317},{"date":"2023-06-30","current":-6.279244,"twenty":-7.759469,"median":-5.62503,"eighty":-4.565397,"marketCap":499947091},{"date":"2023-07-07","current":-6.658667,"twenty":-7.721758,"median":-5.636859,"eighty":-4.57261,"marketCap":530156377},{"date":"2023-07-14","current":-6.737887,"twenty":-7.69008,"median":-5.655758,"eighty":-4.584244,"marketCap":536463810},{"date":"2023-07-21","current":-7.325784,"twenty":-7.579961,"median":-5.662109,"eighty":-4.599308,"marketCap":583271606},{"date":"2023-07-28","current":-6.971378,"twenty":-7.548286,"median":-5.680564,"eighty":-4.620996,"marketCap":555054140},{"date":"2023-08-04","current":-6.024905,"twenty":-7.53565,"median":-5.7162,"eighty":-4.635607,"marketCap":479696910},{"date":"2023-08-11","current":-6.317571,"twenty":-7.508508,"median":-5.728214,"eighty":-4.646146,"marketCap":520365665},{"date":"2023-08-18","current":-6.081084,"twenty":-7.503806,"median":-5.74007,"eighty":-4.685973,"marketCap":500886743},{"date":"2023-08-25","current":-6.565311,"twenty":-7.485744,"median":-5.747894,"eighty":-4.706554,"marketCap":540771554},{"date":"2023-09-01","current":-5.939851,"twenty":-7.432417,"median":-5.767385,"eighty":-4.717317,"marketCap":489253674},{"date":"2023-09-08","current":-5.90757,"twenty":-7.394936,"median":-5.767385,"eighty":-4.729611,"marketCap":486594686},{"date":"2023-09-15","current":-6.125472,"twenty":-7.334123,"median":-5.776163,"eighty":-4.737938,"marketCap":504542851},{"date":"2023-09-22","current":-5.491941,"twenty":-7.325784,"median":-5.777303,"eighty":-4.750864,"marketCap":452360224},{"date":"2023-09-29","current":-6.528994,"twenty":-7.315985,"median":-5.798618,"eighty":-4.757855,"marketCap":537780193},{"date":"2023-10-06","current":-5.891429,"twenty":-7.305739,"median":-5.815592,"eighty":-4.762744,"marketCap":485265193},{"date":"2023-10-13","current":-5.245793,"twenty":-7.264602,"median":-5.81239,"eighty":-4.76989,"marketCap":432085446},{"date":"2023-10-20","current":-5.911605,"twenty":-7.242394,"median":-5.819157,"eighty":-4.778229,"marketCap":486927060},{"date":"2023-10-27","current":-5.61098,"twenty":-7.227384,"median":-5.819157,"eighty":-4.783375,"marketCap":462165240},{"date":"2023-11-03","current":-6.323198,"twenty":-7.199866,"median":-5.83392,"eighty":-4.792261,"marketCap":520829149},{"date":"2023-11-10","current":-24.667435,"twenty":-7.289284,"median":-5.845821,"eighty":-4.795681,"marketCap":537010063},{"date":"2023-11-17","current":-23.534356,"twenty":-7.370611,"median":-5.860692,"eighty":-4.801055,"marketCap":512342934},{"date":"2023-11-24","current":-17.593348,"twenty":-7.503806,"median":-5.888899,"eighty":-4.80845,"marketCap":383007177},{"date":"2023-12-01","current":-19.859506,"twenty":-7.579961,"median":-5.902072,"eighty":-4.82304,"marketCap":432341435},{"date":"2023-12-08","current":-20.456669,"twenty":-7.795672,"median":-5.911605,"eighty":-4.834509,"marketCap":445341678},{"date":"2023-12-15","current":-21.421317,"twenty":-7.911691,"median":-5.925612,"eighty":-4.846375,"marketCap":466342072},{"date":"2023-12-22","current":-22.600332,"twenty":-8.347461,"median":-5.932462,"eighty":-4.855589,"marketCap":492009220},{"date":"2023-12-29","current":-25.126791,"twenty":-8.454865,"median":-5.939851,"eighty":-4.857715,"marketCap":547010250},{"date":"2024-01-05","current":-21.5285,"twenty":-8.540017,"median":-5.941515,"eighty":-4.868537,"marketCap":468675449},{"date":"2024-01-12","current":-24.698059,"twenty":-8.846163,"median":-5.963335,"eighty":-4.891549,"marketCap":537676742},{"date":"2024-01-19","current":-22.952505,"twenty":-8.966963,"median":-5.978768,"eighty":-4.905676,"marketCap":499676030},{"date":"2024-01-26","current":-22.814698,"twenty":-9.138499,"median":-5.992309,"eighty":-4.915832,"marketCap":496675974},{"date":"2024-02-02","current":-22.615644,"twenty":-9.581677,"median":-6.004236,"eighty":-4.91911,"marketCap":492342559},{"date":"2024-02-09","current":-22.217535,"twenty":-10.307241,"median":-6.016566,"eighty":-4.921856,"marketCap":483675730},{"date":"2024-02-16","current":-22.99844,"twenty":-11.237955,"median":-6.024748,"eighty":-4.926434,"marketCap":500676049},{"date":"2024-02-23","current":-20.272926,"twenty":-11.577357,"median":-6.028302,"eighty":-4.929152,"marketCap":441341603},{"date":"2024-03-01","current":-20.257614,"twenty":-12.836913,"median":-6.037413,"eighty":-4.93164,"marketCap":441008264},{"date":"2024-03-08","current":-19.262342,"twenty":-13.485547,"median":-6.058862,"eighty":-4.948141,"marketCap":419341191},{"date":"2024-03-15","current":-61.321385,"twenty":-15.009082,"median":-6.081084,"eighty":-4.952685,"marketCap":409933456},{"date":"2024-03-22","current":-65.487505,"twenty":-17.593348,"median":-6.089351,"eighty":-4.961191,"marketCap":437783972},{"date":"2024-03-28","current":-69.405148,"twenty":-18.101359,"median":-6.099956,"eighty":-4.961191,"marketCap":463973412},{"date":"2024-04-05","current":-66.890118,"twenty":-18.959167,"median":-6.113366,"eighty":-4.968258,"marketCap":447160438},{"date":"2024-04-12","current":-64.133258,"twenty":-19.427711,"median":-6.12749,"eighty":-4.972184,"marketCap":428730832},{"date":"2024-04-19","current":-57.740708,"twenty":-19.862568,"median":-6.151102,"eighty":-4.983342,"marketCap":385996632},{"date":"2024-04-26","current":-59.922347,"twenty":-20.184117,"median":-6.16971,"eighty":-4.990199,"marketCap":400580888},{"date":"2024-05-03","current":-65.74005,"twenty":-20.444419,"median":-6.184272,"eighty":-4.992718,"marketCap":439472236},{"date":"2024-05-10","current":19.415556,"twenty":-20.444419,"median":-6.175043,"eighty":-4.972184,"marketCap":455974329},{"date":"2024-05-17","current":20.21327,"twenty":-20.380109,"median":-6.165519,"eighty":-4.951776,"marketCap":474708650},{"date":"2024-05-24","current":20.307914,"twenty":-20.2913,"median":-6.137664,"eighty":-4.92478,"marketCap":476931366},{"date":"2024-05-31","current":21.13267,"twenty":-20.263739,"median":-6.121053,"eighty":-4.910399,"marketCap":496300749},{"date":"2024-06-07","current":21.36252,"twenty":-20.202491,"median":-6.101682,"eighty":-4.850628,"marketCap":501698774},{"date":"2024-06-14","current":22.241358,"twenty":-20.073872,"median":-6.099956,"eighty":-4.811533,"marketCap":522338281},{"date":"2024-06-21","current":19.523721,"twenty":-19.926878,"median":-6.084547,"eighty":-4.791677,"marketCap":458514576},{"date":"2024-06-28","current":21.190193,"twenty":-19.908503,"median":-6.084547,"eighty":-4.774893,"marketCap":497651675},{"date":"2024-07-05","current":21.220101,"twenty":-19.884004,"median":-6.074028,"eighty":-4.75366,"marketCap":498354077},{"date":"2024-07-12","current":25.975557,"twenty":-19.868693,"median":-6.049635,"eighty":-4.708476,"marketCap":610035963},{"date":"2024-07-15","current":25.646563,"twenty":-19.86563,"median":-6.041344,"eighty":-4.695302,"marketCap":602309543},{"date":"2024-08-02","current":23.867006,"twenty":-19.862568,"median":-6.039378,"eighty":-4.672517,"marketCap":560516636},{"date":"2024-08-09","current":21.608912,"twenty":-19.826255,"median":-6.030346,"eighty":-4.59214,"marketCap":507485300},{"date":"2024-08-16","current":5.477968,"twenty":-19.64186,"median":-6.024748,"eighty":-4.554742,"marketCap":572140896},{"date":"2024-08-23","current":5.427433,"twenty":-19.500935,"median":-6.016566,"eighty":-4.515022,"marketCap":566862843},{"date":"2024-08-30","current":5.895722,"twenty":-19.427711,"median":-6.004236,"eighty":-4.471291,"marketCap":615772797},{"date":"2024-09-06","current":5.184866,"twenty":-19.32359,"median":-5.996942,"eighty":-4.404766,"marketCap":541528191},{"date":"2024-09-13","current":5.00631,"twenty":-19.188845,"median":-5.984239,"eighty":-4.33112,"marketCap":522879072},{"date":"2024-09-20","current":5.053476,"twenty":-19.038789,"median":-5.963335,"eighty":-4.288277,"marketCap":527805255},{"date":"2024-09-27","current":5.312888,"twenty":-18.96223,"median":-5.941515,"eighty":-4.265242,"marketCap":554899258},{"date":"2024-10-04","current":5.53861,"twenty":-18.944963,"median":-5.936157,"eighty":-4.226961,"marketCap":578474559},{"date":"2024-10-11","current":5.326364,"twenty":-18.856806,"median":-5.931781,"eighty":-4.189868,"marketCap":556306738},{"date":"2024-10-18","current":5.939519,"twenty":-18.609029,"median":-5.915524,"eighty":-4.126724,"marketCap":620347109},{"date":"2024-10-25","current":5.673369,"twenty":-18.19595,"median":-5.907226,"eighty":-4.100192,"marketCap":592549366},{"date":"2024-10-31","current":5.80476,"twenty":-17.843071,"median":-5.891429,"eighty":-4.019982,"marketCap":606272302},{"date":"2024-11-08","current":12.390042,"twenty":-17.597525,"median":-5.862704,"eighty":-3.976074,"marketCap":680845207},{"date":"2024-11-15","current":12.267624,"twenty":-17.595854,"median":-5.851076,"eighty":-3.881511,"marketCap":674118187},{"date":"2024-11-22","current":11.629759,"twenty":-17.593348,"median":-5.835599,"eighty":-3.819187,"marketCap":639066874},{"date":"2024-11-29","current":12.815285,"twenty":-17.245441,"median":-5.821992,"eighty":-3.767275,"marketCap":704212749},{"date":"2024-12-06","current":13.092338,"twenty":-15.736155,"median":-5.81239,"eighty":-3.495412,"marketCap":719437057},{"date":"2024-12-13","current":11.67486,"twenty":-15.214231,"median":-5.797942,"eighty":-3.367358,"marketCap":641545250},{"date":"2024-12-20","current":11.133642,"twenty":-14.879355,"median":-5.778442,"eighty":-3.167818,"marketCap":611804741},{"date":"2024-12-27","current":11.430023,"twenty":-14.360448,"median":-5.768112,"eighty":-2.950607,"marketCap":628091210},{"date":"2025-01-03","current":11.249617,"twenty":-13.956183,"median":-5.754982,"eighty":-2.907357,"marketCap":618177707},{"date":"2025-01-10","current":10.450675,"twenty":-13.687679,"median":-5.750196,"eighty":-2.871796,"marketCap":574275052},{"date":"2025-01-17","current":8.079622,"twenty":-13.52175,"median":-5.745698,"eighty":4.66739,"marketCap":443983302},{"date":"2025-01-24","current":8.324459,"twenty":-13.470462,"median":-5.734949,"eighty":4.930845,"marketCap":457437341},{"date":"2025-01-31","current":8.614397,"twenty":-13.333193,"median":-5.728214,"eighty":5.00631,"marketCap":473369756},{"date":"2025-02-07","current":8.685271,"twenty":-13.061672,"median":-5.704997,"eighty":5.067626,"marketCap":477264347},{"date":"2025-02-14","current":8.13761,"twenty":-12.882167,"median":-5.680564,"eighty":5.23877,"marketCap":447169785},{"date":"2025-02-21","current":8.421105,"twenty":-12.823337,"median":-5.663281,"eighty":5.326364,"marketCap":462748146},{"date":"2025-02-28","current":6.463236,"twenty":-12.636289,"median":-5.655945,"eighty":5.420021,"marketCap":424156296},{"date":"2025-03-07","current":5.656685,"twenty":-12.097773,"median":-5.638438,"eighty":5.496161,"marketCap":371225587},{"date":"2025-03-14","current":5.873832,"twenty":-11.969554,"median":-5.62503,"eighty":5.544674,"marketCap":385476089},{"date":"2025-03-21","current":5.651256,"twenty":-11.577357,"median":-5.617686,"eighty":5.571626,"marketCap":370869324},{"date":"2025-03-28","current":5.406965,"twenty":-11.517019,"median":-5.599973,"eighty":5.615422,"marketCap":354837509},{"date":"2025-04-04","current":4.353801,"twenty":-11.27265,"median":-5.589567,"eighty":5.571626,"marketCap":285722573},{"date":"2025-04-11","current":4.261514,"twenty":-11.237955,"median":-5.571525,"eighty":5.568257,"marketCap":279666109},{"date":"2025-04-17","current":4.266943,"twenty":-11.147449,"median":-5.559289,"eighty":5.565562,"marketCap":280022372},{"date":"2025-04-25","current":4.864097,"twenty":-11.079568,"median":-5.509464,"eighty":5.565562,"marketCap":319211253},{"date":"2025-04-29","current":4.815239,"twenty":-10.961909,"median":-5.502472,"eighty":5.557476,"marketCap":316004890}],"updateTime":1746035876016}}}